TickerGuard
Buy Day today: Poor (58) Mixed market breadth · today: CPI (July)
DRS

Leonardo DRS, Inc. Common Stock

Industrials · Aerospace & Defense

44.70$ -0.9% vs. previous close Closing price · As of: Aug 11, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Leonardo DRS, Inc. Common Stock (DRS). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — DRS
Segment 2020 2021 2022 2023 2024 2025
ASC $1.96B 70.1% $1.94B 66.9% · -0.9% $1.73B 63.8% · -10.7% $1.83B 64.2% · +5.7% $2.12B 65.0% · +15.7% $2.36B 64.3% · +11.2%
IMS $834.0M 29.9% $959.0M 33.1% · +15.0% $983.0M 36.2% · +2.5% $1.02B 35.8% · +3.9% $1.14B 35.0% · +11.5% $1.31B 35.7% · +14.9%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Operating income — DRS
Segment 2020 2021 2022 2023 2024 2025
ASC $503.0M 29.0% $136.0M 7.4% $183.0M 8.6% $240.0M 10.2%
IMS $101.0M 10.3% $92.0M 9.0% $117.0M 10.3% $115.0M 8.8%

Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.

Revenue by product line

Revenue by product line — DRS
Segment 2020 2021 2022 2023
Products $2.41B 86.8% $2.51B 87.0% · +3.9% $2.44B 90.7% · -2.5% $2.63B 93.1% · +7.7%
Services $366.0M 13.2% $374.0M 13.0% · +2.2% $250.0M 9.3% · -33.2% $195.0M 6.9% · -22.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?